50050 WiOn New Indoor App w Timer Programmable Switch, Wireless Outlet, Wi-Fi Electrical Outlet Timers


  1. Home
  2. 50050 WiOn New Indoor App w Timer Programmable Switch, Wireless Outlet, Wi-Fi
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
New WiOn 50050 Indoor Wi-Fi Outlet, Wireless Switch, Programmable Timer w App
Condition: New: A brand-new, unused, unopened, undamaged item in its original packaging (where packaging is Brand:

WiOn

ISBN:

Does not apply

Manufacturer: WiOn
MPN:

Does Not Apply

Model:

50050

UPC:

078693500503

EAN:

0078693500503






published on tue nov 09 2021

50050 WiOn New Indoor App w Timer Programmable Switch, Wireless Outlet, Wi-Fi Electrical Outlet Timers

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

50050 WiOn New Indoor App w Timer Programmable Switch, Wireless Outlet, Wi-Fi Electrical Outlet Timers

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS